CCM
TXMD icon

Cadian Capital Management’s TherapeuticsMD TXMD Stock Holding History

Cadian Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,000
Closed -$3.15M – 94
2014
Q1 		$3.15M Buy
+10,000
New +$3.18M 0.08% 74

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cadian Capital Management's TXMD Position: Q2 2014 in Review

Cadian Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2014, closing a stake of 10,000 shares — an estimated $3.15M sold.

Cadian Capital Management first reported a position in TXMD in Q1 2014 and held it in 1 quarter. The position peaked at $3.15M in Q1 2014. 87 funds tracked by Wall St. Rank hold TXMD as of Q2 2014.

  • Cadian Capital Management reported no remaining TherapeuticsMD position as of Q2 2014 after selling out during the quarter.
  • Cadian Capital Management sold 10,000 TherapeuticsMD shares in Q2 2014, an estimated $3.15M.
  • Cadian Capital Management first reported a position in TherapeuticsMD in Q1 2014 and held it in 1 quarter.
  • Cadian Capital Management's TherapeuticsMD position peaked at $3.15M in Q1 2014.
  • 87 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2014.

Based on Cadian Capital Management's 13F filing for Q2 2014, filed 13 Aug 2014.